B16F10/ESAT-6-GPI-IL-21瘤苗安全性及抗肿瘤效应研究

Study of safety and anti-tumor efficacy of B16F10/ESAT-6-GPI-IL-21 tumour vaccine in mouse model

目的:评估B16F10/ESAT-6-GPI-IL-21瘤苗用于C57BL/6小鼠的安全性及其诱导的抗肿瘤免疫效应。方法:应用免疫荧光、FCM检测瘤苗细胞ESAT-6-GPI的表达情况;以Western blot方法检测瘤苗细胞IL-21的表达情况;动物实验检测瘤苗体内应用的安全性;制备荷瘤鼠术后免疫模型,评价瘤苗免疫效果。结果:B16F10/ESAT-6-GPI-IL-21瘤苗细胞表面有靶抗原ESAT-6-GPI表达,并分泌IL-21。于C57BL/6小鼠皮下接种2×105个B16F10/ESAT-6-GPI-IL-21瘤苗细胞,60天内未见致瘤,但能够诱导小鼠产生有效的抗肿瘤免疫效应。结论:B16F10/ESAT-6-GPI-IL-21瘤苗致瘤性明显下降,低剂量应用具有安全性,能够诱导小鼠产生有效的抗肿瘤免疫效应。

Objective：The safety and anti-tumor efficacy of B16F10/ESAT-6-GPI-IL-21 tumour vaccine in mouse model was evaluated.Methods：Expressions of ESAT-6-GPI antigen of tumour vaccine were detected by immunofluorescence and flow cytometry,respectively.Expression of IL-21 of tumour vaccine were detected by Western blot.The biological safety of tumour vaccine was evaluated by animal experiments.The developed postoperative bearing-tumor mice were immunized with the tumour vaccine and the efficacy of B16F10/ESAT-6-GPI-IL-21 vaccine against B16F10 cell challenge was also evaluated.Results：Target antigen of ESAT-6-glycosyl phosphatidyl inositol（gpi） was expressed on the surface of B16F10/ESAT-6-GPI-IL-21 tumour vaccine that secreted IL-21 simultaneouly.There were no tumour formation in mice vaccinated with 2×105 B16F10/ESAT-6-GPI-IL-21 tumour vaccine after 60 days into the observation.The vaccine could generate a powerful immune efficiency against the B16F10 tumor cell challenge.Conclusion：B16F10/ESAT-6-GPI-IL-21 tumour vaccine oncogenicity is very low and has a safety characteristic when it is applied into mouse model in low dose.